Plenary Session: US Pharmaceutical Policy: Leading or Following?
Moderator
Dana P. Goldman, PhD, University of Southern California Schaeffer Institute for Public Policy & Government Service, Los Angeles, CA, United States
Speakers
Courtney Piron, Novartis, Washington, DC, United States; Liz Fowler, PhD, JD, Johns Hopkins Bloomberg School of Public Health, Arlington, VA, United States; Inmaculada Hernandez, PhD, CMS, Washington, DC, United States
Americans have run out of patience with paying three times more for innovative medicine than other developed countries. President Trump is negotiating ways to bring US drug prices in line with other countries through a most-favored-nation (MFN) approach. This strategy follows the Biden Administration's Inflation Reduction Act to directly negotiate drug prices in Medicare. In discussion with current and former Administration officials and the biopharmaceutical industry, we will discuss MFN, the role of intermediaries, cost-sharing, and cell and gene therapies in the United States – with a view toward the economic and regulatory implications and long-term consequences for the US.
Topic
Economic Evaluation, Health Policy & Regulatory, Health Technology Assessment